Vycor Medical, Inc. (VYCO)
- Previous Close
0.0840 - Open
0.0840 - Bid --
- Ask --
- Day's Range
0.0840 - 0.0840 - 52 Week Range
0.0420 - 0.0970 - Volume
728 - Avg. Volume
4,148 - Market Cap (intraday)
2.741M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. Vycor Medical, Inc. has a license and transition agreement with HelferApp GmbH, which grants HelferApp the license to provide NovaVision's products and therapies to patients and professionals in Austria and Switzerland. The company primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.
www.vycormedical.comRelated News
Performance Overview: VYCO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VYCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VYCO
Valuation Measures
Market Cap
2.74M
Enterprise Value
3.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.88
Price/Book (mrq)
--
Enterprise Value/Revenue
2.60
Enterprise Value/EBITDA
37.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.77%
Return on Assets (ttm)
2.71%
Return on Equity (ttm)
--
Revenue (ttm)
1.46M
Net Income Avi to Common (ttm)
-387.45k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
57.29k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
366.4k